Abstract
Objective Immunotherapy has improved outcomes for advanced-stage melanoma, however, predictive biomarkers remain limited. We evaluated whether computed tomography (CT) features from multiple anatomical regions could predict immunotherapy response.
Materials and Methods This study included 157 advanced cutaneous melanoma patients (mean age: 63.3 years; 65.6% male) treated with PD-1 immune checkpoint inhibitor (ICI) singly or in combination with LAG-3 or CTLA-4 ICIs. The primary outcome was 1-year progression-free survival (PFS ≥12 months). Available artificial intelligence (AI) algorithms were applied to pretreatment CT scans to extract and quantify three-dimensional (3D) body composition and thoracic features across abdominal, chest, pelvic regions, and spinal vertebrae. Feature relationship to PFS was assessed. Machine learning (ML) models were used to predict PFS, utilizing only the most important five features to mitigate overfitting. Prediction performance was evaluated using the area under the receiver operating curve (AUROC) with stratified 10-fold cross-validation.
Results Multiple CT features are significantly associated with immunotherapy response. Body tissues at the L5 spinal vertebrae emerged as key predictors. A random forest classifier (RFC) trained on three CT features (L5 bone volume, L5 subcutaneous adipose tissue volume, pelvis visceral adipose tissue density) and two clinical variables achieved a mean AUROC of 0.83 (95% CI: 0.72–0.94). A logistic regression model using the same features yielded an AUROC of 0.82 (95% CI: 0.74–0.91), significantly outperforming a clinical-only model (AUROC 0.65; 95% CI: 0.56–0.74; p=0.006).
Conclusion Integrating imaging features from multiple anatomical regions can improve the prediction of immunotherapy response in advanced melanoma.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by Developmental Research funding through the University of Pittsburgh Melanoma and Skin Cancer SPORE NIH P50 CA254865 and NIH R01CA237277. Sponsors had no involvement in this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of Pittsburgh Institutional Review Board (IRB #: STUDY 21020214).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This work was supported in part by Developmental Research funding through the University of Pittsburgh Melanoma and Skin Cancer SPORE NIH P50 CA254865 and NIH R01CA237277. Sponsors had no involvement in this study.
Conflicts of Interest: None declared
Ethics approval and consent to participate: This study was approved by the University of Pittsburgh Institutional Review Board (IRB #: STUDY 21020214).
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations and Acronyms
- AUROC
- area under the receiver operating characteristic curve
- AUPRC
- area under the precision-recall curve
- M
- machine learning
- VAT
- visceral adipose tissue
- SAT
- subcutaneous adipose tissue
- IMAT
- intramuscular adipose tissue
- SVM
- support vector machine
- MLP
- multilayer perceptron
- RFC
- random forest classifier
- CI
- confidence interval
- BMI
- body mass index
- ICIs
- immune checkpoint inhibitors
- OS
- overall survival
- PFS
- progression-free survival
- RFS
- recurrence-free survival
- LR
- logistic regression
- ANC
- absolute neutrophil count
- ALC
- absolute lymphocyte count
